SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 25.54+1.4%Dec 15 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lance Bredvold who wrote (15894)7/17/2002 12:29:47 PM
From: Cacaito  Read Replies (2) of 17367
 
Bpi retina program is conducted by the Joslin Institute in Boston, one of the worlds most respected institutions in the field.

Bpi could end up being the most effective and less toxic product for macular degeneration. The animal and basic science studies are excellent.

This alone is a very good reason to own xoma and the main reason I followed the company.

Xanelim will sustain the price in the next 2 to 3 years, since is already bottom, it is a reasonable entrance at this point, and a reasonable hold.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext